Brake through to decrease the wait­ing list of organ trans­plan­ta­tion

Dutch-based donor organ per­fu­sion devices companyOrgan Assist BV today announced the suc­cess­ful com­ple­tion of sec­ond round invest­ment led by Dutch investor MedSciences Capital BV from Amsterdam, The Netherlands. Also par­tic­i­pat­ing in this equi­ty invest­ment are De Friesland Zorgverzekeraar NV, Hanzepoort BV, NoordTechVenture BV, Kennisconversiefonds BV and G.J. Smidfonds BV, all from the Netherlands. The financ­ing will enable Organ Assist to bring its first prod­ucts to mar­ket and to fur­ther devel­op their extend­ed prod­uct line.

The ever-grow­ing wait­ing list for organ trans­plan­ta­tion express­es the need for improved avail­abil­i­ty. Organ Assist ful­fils this need by improv­ing the pos­si­bil­i­ty for less opti­mal organs to be includ­ed in the donor pool by improv­ing their qual­i­ty. It is expect­ed that the donor pool will thus be increased by 30%. Organ Assist’s patent-pro­tect­ed sys­tems allow con­trolled donor organ pro­cure­ment as well as improved preser­va­tion of donor kid­neys and liv­ers in donor clin­ics and dur­ing trans­porta­tion.

By imple­ment­ing advanced blood pump and oxy­gena­tion tech­niques in the OA trans­port box­es, the donor organs are pro­tect­ed against loss of qual­i­ty. The Organ Assist prod­ucts proved to be ben­e­fi­cial in pre­clin­i­cal eval­u­a­tions at part­ner insti­tutes around the world, and is now await­ing its clin­i­cal intro­duc­tion in EU and USA. “We are extreme­ly pleased with the sup­port of these pro­fes­sion­al investors in turn­ing our inno­va­tions into world­wide avail­able and real­ly mean­ing­ful health­care prod­ucts,” said prof.dr. Gerhard Rakhorst, CEO and founder of Organ Assist. “Next to finan­cial input, they pro­vide access to exper­tise that we regard as essen­tial to the growth of our com­pa­ny.”

Mr. Wilem van Lawick from MedSciences Capital and chair­man of the Board of Directors of Organ Assist BV, added: ”Organ Assist, with its poten­tial to gen­er­ate sig­nif­i­cant returns in the near term, illus­trates the attrac­tive­ness of med­ical tech­nol­o­gy as an invest­ment oppor­tu­ni­ty. But more impor­tant­ly, with this invest­ment, we con­tribute to solv­ing one of the major issues of this era: the high wait­ing list for organ trans­plan­ta­tion.”

The oth­er Members of the Board of Directors are Mr. R. Feenstra from De Friesland Zorgverzekeraar NV and Mr. Dantuma from G.J. Smidfonds BV.

Leave a Reply

Your email address will not be published. Required fields are marked *